A Phase 4 interventional study of fluticasone propionate/salmeterol (FSC) and montelukast (MON) in Asthma, sponsored by GlaxoSmithKline. Completed at 121 sites in 4 countries. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2016-12-16.
Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 15th largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2005, is one of 52 in phase 4, and was the 13th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 15 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 9 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 725 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 16th largest by enrollment of the 238 interventional ones that give a count, is one of 17 that started in 2005, is one of 53 in phase 4, and was the 12th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.
A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD versus Montelukast 10mg QD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A subject will be considered eligible for inclusion in this study only if all of the following criteria apply:
Asthma is a clinical syndrome characterized by increased responsiveness of the tracheobronchial tree to a variety of stimuli. The major symptoms of asthma are paroxysms of dyspnea, wheezing, and cough, which may vary from mild and almost undetectable to severe and unremitting (status asthmaticus). The primary physiological manifestation of this hyperresponsiveness is variable airway obstruction. This can take the form of spontaneous fluctuations in the severity of obstruction, substantial improvements in the severity of obstruction following bronchodilators or , or increased obstruction caused by drugs or other stimuli [American Thoracic Society, 1987a].
NOTE: Intermittent and seasonal asthma, as well as exercise-induced bronchospasm alone, are excluded.
Asthma Therapy: 3 months' prior and current use of one of the following asthma therapies, with no change in regimen during the month prior to Visit 1:
criteria.
Inhaled Corticosteroid (Total Daily Dose) Beclomethasone dipropionate (≤420mcg) Beclomethasone dipropionate HFA (≤240mcg) Budesonide (≤400mcg) Flunisolide (≤1000mcg) Fluticasone propionate inhalation aerosol (≤220mcg) Fluticasone propionate inhalation powder (≤250mcg) Mometasone furoate (≤220mcg) Triamcinolone acetonide (≤1000mcg) Subjects taking ADVAIR 100/50mcg BID are eligible to replace ADVAIR with FLOVENT HFA 110mcg BID for 14 days prior to Visit 1. This change will be at the Investigator's clinical discretion, taking each individual's current and past asthma stability into account. The subject must be aware of the risks and benefits of switching their medication and acknowledge this by signing an informed consent prior to any change in the subject's medication regimen.
At Visit 2, subjects must also be experiencing minimum asthma symptoms as defined in Section 5.2.3, "Randomization Criteria", and in Section 6.2 of the protocol.
Predicted FEV1 will be based on the National Health and Nutrition Examination Survey (NHANES III) predicted normal values [Hankinson, 1999].
Rhinitis Diagnosis: A diagnosis of seasonal allergic rhinitis defined as follows:
AND •A positive skin test reaction to a geographically relevant seasonal allergen, as determined by the skin prick method, within 24 months prior to or at Visit 1.
For the purposes of this study, a positive skin test reaction is defined as a wheal diameter that is at least 3mm greater than diluent control using 1:20 W:V glycerinated solution.
•At Visit 2, subjects must also be experiencing minimum rhinitis symptoms as defined in Section 5.2.3, "Randomization Criteria", and in Section 6.2 of the protocol.
Note: The principal investigator is responsible for tracking and recording pollen counts for geographically relevant seasonal allergens throughout the entire study. Alternatively, this information may be obtained from a reputable source from within the same geographical area.
EXCLUSION CRITERIA:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
The list of additional excluded conditions/diseases includes, but is not limited to: cardiac arrhythmias; congestive heart failure; coronary artery disease; poorly controlled diabetes, poorly controlled hypertension, poorly controlled peptic ulcer, hematologic, hepatic, or renal disease; immunologic compromise; current ; current or quiescent tuberculosis, and Cushing's or Addison's disease.
Concurrent Medications: Concurrent use of any of the following medications that may affect the course of asthma, rhinitis, or interact with sympathomimetic amines or montelukast.
NOTE: Topical hydrocortisone cream or ointment (1% or less) is permitted during the study.
Medication (Exclusion Period Prior to Visit 1) Intranasal and ocular corticosteroids (28 days) Leukotriene modifiers (e.g., Singulair, Accolate, Zyflo) (28 days) Intranasal and ocular cromolyn (14 days) Long-acting antihistamines (e.g., loratadine, cetirizine) (10 days) Short-acting antihistamines (includes prescription and OTC) (72 hours) Oral and intranasal decongestants (72 hours) Intranasal anticholinergics (e.g., Atrovent) (24 hours)
These asthma medications, with the exception of an inhaled corticosteroid/long-acting beta2-agonist combination product and Xolair, may be continued during the run-in period of the study (between Visits 1 and 2), but must be withheld prior to Visit 2 for the appropriate "exclusion period" as shown below.
These asthma medications are not allowed any time after randomization at Visit 2 (with the exception of as as-needed rescue albuterol/salbutamol), unless dispensed as double-blind study drug:
Medicationª (Exclusion Period Prior to Visit 1 and/or Visit 2) Inhaled corticosteroid/long-acting beta2-agonist combination product (e.g., ADVAIR) (14 days) Inhaled anticholinergics (e.g., Atrovent, Combivent, Spiriva) (24 hours) Theophylline products (48 hours) Inhaled cromolyn or nedocromil (24 hours) Inhaled corticosteroids (12 hours) Long-acting beta2-agonists (e.g., Foradil, SEREVENT™) (14 days) Oral beta2-agonists (12 hours) Inhaled short-acting beta2-agonists\^b (e.g., Proventil) (6 hours) Xolair (12 months)
Replaced at Visit 1 with albuterol/salbutamol.
NOTE: Immunotherapy for the treatment of allergies is allowed during the study, provided that it was not initiated within 30 days of Visit 1, the dose has remained fixed over the 30 days prior to Visit 1, and the dose will remain fixed for the duration of the study.
Note: Pack years = number of cigarettes smoked per day divided by 20, multiplied by the number of years of smoking.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fluticasone propionate/salmeterol DISKUS combination product (FSC) twice daily (BID) plus vehicle placebo nasal spray once daily (QD) plus montelukast capsule 10mg (MON) QD
Drug: fluticasone propionate/salmeterol (FSC) · Drug: montelukast (MON) · Drug: placebo nasal · Drug: ADVAIR DISKUS
FSC BID plus vehicle placebo nasal spray QD plus placebo capsule QD
Drug: fluticasone propionate/salmeterol (FSC) · Drug: placebo nasal · Drug: ADVAIR DISKUS · Drug: placebo capsule
Fluticasone propionate/salmeterol DISKUS combination product (FSC)100/50mcg BID plus fluticasone propionate aqueous nasal spray 200mcg (FPANS) QD plus placebo capsule QD
Drug: fluticasone propionate/salmeterol (FSC) · Drug: fluticasone propionate (FP) · Drug: ADVAIR DISKUS · Drug: placebo capsule
Placebo DISKUS BID plus vehicle placebo nasal spray QD plus MON QD
Drug: montelukast (MON) · Drug: placebo nasal · Drug: placebo DISKUS
Drug pages: Fluticasone · Salmeterol Xinafoate
fluticasone propionate/salmeterol DISKUS combination
montelukast capsule
fluticasone propionate aqueous nasal spray
vehicle placebo nasal spray
ADVAIR DISKUS
placebo capsule
placebo DISKUS
Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population
Endpoint was defined as the average of the data reported from the last week of treatment. Data collected by patient throughout the treatment period between visits. The peak expiratory flow rate measures how fast a person can breathe out (exhale) air. It is one of many tests that measure how well your airways work.
Time frame: Baseline to Endpoint (weeks 3-4)
Mean Change From Baseline at Endpoint in Morning Peak Expiratory Flow (PEF) for Per Protocol Population
Endpoint was defined as the average of the data reported from the last week of treatment. Data collected by patient throughout the treatment period between visits. The peak expiratory flow rate measures how fast a person can breathe out (exhale) air. It is one of many tests that measure how well your airways work.
Time frame: Baseline to Endpoint (weeks 3-4)
Rhinitis: Mean Change From Baseline at 1-2 Weeks in Daytime Total Nasal Symptom Scores (D-TNNS).
The sum of scores of each of the four daytime symptoms (nasal congestion, itching, rhinorrhea, and sneezing). Scale: 0=none (no sign/symptom evident)1=mild (sign/symptom clearly present; easily tolerated)2=moderate (definite awareness of sign/symptom that is bothersome but tolerable)3=severe (sign/symptom is hard to tolerate)
Time frame: Baseline to 1-2 Weeks
Rhinitis: Mean Change From Baseline at 1-2 Weeks in Nightime Total Nasal Symptom Scores (N-TNSS)
The scores of 3 nighttime symptoms (nasal congestion upon awakening, difficulty going to sleep due to nasal symptoms, nighttime awakenings due to nasal symptoms). Scale: 0=not noticeable, 1=noticeable but not bothersome, 2=noticeable and bothersome some of the time, 3=bothersome most of the time and/or very bothersome some of the time.
Time frame: Baseline To 1-2 Weeks
Asthma: Mean Change From Baseline at Endpoint in Predose Morning Forced Expiratory Volume (FEV1) for Intent-to-Treat Population
Endpoint was defined as the average of the last week's worth of evaluable data. The volume of air that can be forced out taking a deep breath, an important measure of pulmonary function. FEV1 is forced expiratory volume in one second.
Time frame: Baseline to Endpoint (weeks 3-4)
Asthma: Mean Change From Baseline at Endpoint in Predose Morning Forced Expiratory Volume (FEV1) for Per Protocol Population
Endpoint was defined as the average of the last week's worth of evaluable data. The volume of air that can be forced out taking a deep breath, an important measure of pulmonary function. FEV1 is forced expiratory volume in one second.
Time frame: Baseline to Endpoint (weeks 3-4)
Asthma: Mean Change From Baseline at Endpoint in Percentage of Asthma Symptom-Free Days for Intent-to-Treat Population
Endpoint was defined as the average of the data reported from the last week of treatment.Asthma symptom scores and the subject-rated overall satisfaction with treatment, related to the percentage of asthma symptom-free days. Same scale used as in outcome 8.
Time frame: Baseline to Endpoint (weeks 3-4)
Asthma: Mean Change From Baseline at Endpoint in Percentage of Asthma Symptom-Free Days for Per Protocol Population
Asthma symptom score:0=no symptoms,1=symptoms 1 short period,2=symptoms 2 or more short periods,3=symptoms most of day not affect activities,4=symptoms most of day did affect activities,5=symptoms severe.Overall satisfaction score:0=very dissatisfied,1=dissatisfied,2=slightly dissatisfied,3=neutral,4=slightly satisfied,5=satisfied 6=very satisfied
Time frame: Baseline to Endpoint (weeks 3-4)
Asthma: Mean Change From Baseline at Endpoint in Percentage of Albuterol-Salbutamol Free Days for Intent-to-Treat Population
Endpoint was defined as the average of the data reported from the last week of treatment. Albuterol/salbutamol use (related to percentage of asthma rescue-free days).
Time frame: Baseline to Endpoint (weeks 3-4)
Asthma: Mean Change From Baseline at Endpoint in Percentage of Albuterol/Salbutamol-Free Days for Per Protocol Population
Endpoint was defined as the average of the data reported from the last week of treatment. Albuterol/salbutamol use (related to percentage of asthma rescue-free days).
Time frame: Baseline to Endpoint (weeks 3-4)
| Milestone | Flut Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS) | Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | Fluticasone Propionate/Salmeterol (FSC) | Montelukast (MON) |
|---|---|---|---|---|
| Started | 182 | 182 | 180 | 181 |
| Completed | 140 | 129 | 137 | 138 |
| Not completed | 42 | 53 | 43 | 43 |
| Withdrew: Low pollen counts | 18 | 26 | 25 | 16 |
| Withdrew: Protocol violation | 4 | 6 | 2 | 3 |
| Withdrew: Adverse event | 1 | 3 | 1 | 4 |
| Withdrew: Withdrawn due to asthma | 0 | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 7 | 3 | 3 | 2 |
| Withdrew: Non-compliance | 12 | 13 | 10 | 14 |
| Withdrew: Lost to follow-up | 0 | 2 | 2 | 0 |
Endpoint was defined as the average of the data reported from the last week of treatment. Data collected by patient throughout the treatment period between visits. The peak expiratory flow rate measures how fast a person can breathe out (exhale) air. It is one of many tests that measure how well your airways work.
| L/min | Fluticasone Prop/Salmeterol (FSC) | Montelukast (MON) |
|---|---|---|
| Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population | 26.4 ± 4.10 | 3.6 ± 3.28 |
Endpoint was defined as the average of the data reported from the last week of treatment. Data collected by patient throughout the treatment period between visits. The peak expiratory flow rate measures how fast a person can breathe out (exhale) air. It is one of many tests that measure how well your airways work.
| L/min | Flut Prop/Salmeterol/Montelukast (FSC+MON) | Fluticasone Propionate/Salmeterol (FSC) |
|---|---|---|
| Mean Change From Baseline at Endpoint in Morning Peak Expiratory Flow (PEF) for Per Protocol Population | 30.9 ± 4.92 | 35.2 ± 6.41 |
The sum of scores of each of the four daytime symptoms (nasal congestion, itching, rhinorrhea, and sneezing). Scale: 0=none (no sign/symptom evident)1=mild (sign/symptom clearly present; easily tolerated)2=moderate (definite awareness of sign/symptom that is bothersome but tolerable)3=severe (sign/symptom is hard to tolerate)
| Points on a Scale | Fluticasone Prop/Salmeterol/Montelukast (FSC+MON) | Fluticasone Prop/Salmeterol/Flut Nasal Spray (FSC+FPANS) |
|---|---|---|
| Rhinitis: Mean Change From Baseline at 1-2 Weeks in Daytime Total Nasal Symptom Scores (D-TNNS). | -2.3 ± 0.16 | -3.0 ± 0.18 |
The scores of 3 nighttime symptoms (nasal congestion upon awakening, difficulty going to sleep due to nasal symptoms, nighttime awakenings due to nasal symptoms). Scale: 0=not noticeable, 1=noticeable but not bothersome, 2=noticeable and bothersome some of the time, 3=bothersome most of the time and/or very bothersome some of the time.
| Points on a Scale | Flut Prop/Salmeterol/Flut Nasal Spray (FSC+FPANS) | Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) |
|---|---|---|
| Rhinitis: Mean Change From Baseline at 1-2 Weeks in Nightime Total Nasal Symptom Scores (N-TNSS) | -2.0 ± 0.13 | 1.7 ± 0.13 |
Endpoint was defined as the average of the last week's worth of evaluable data. The volume of air that can be forced out taking a deep breath, an important measure of pulmonary function. FEV1 is forced expiratory volume in one second.
| L/sec | Fluticasone Propionate/Salmeterol (FSC) | Montelukast (MON) |
|---|---|---|
| Asthma: Mean Change From Baseline at Endpoint in Predose Morning Forced Expiratory Volume (FEV1) for Intent-to-Treat Population | 0.15 ± 0.02 | 0.04 ± 0.03 |
Endpoint was defined as the average of the last week's worth of evaluable data. The volume of air that can be forced out taking a deep breath, an important measure of pulmonary function. FEV1 is forced expiratory volume in one second.
| L/sec | Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | Fluticasone Propionate/Salmeterol (FSC) |
|---|---|---|
| Asthma: Mean Change From Baseline at Endpoint in Predose Morning Forced Expiratory Volume (FEV1) for Per Protocol Population | 0.27 ± 0.04 | 0.13 ± 0.04 |
Endpoint was defined as the average of the data reported from the last week of treatment.Asthma symptom scores and the subject-rated overall satisfaction with treatment, related to the percentage of asthma symptom-free days. Same scale used as in outcome 8.
| Percentage of asthma symptom-free days | Fluticasone Propionate/Salmeterol (FSC) | Montelukast (MON) |
|---|---|---|
| Asthma: Mean Change From Baseline at Endpoint in Percentage of Asthma Symptom-Free Days for Intent-to-Treat Population | 34.8 ± 2.94 | 26.1 ± 2.83 |
Asthma symptom score:0=no symptoms,1=symptoms 1 short period,2=symptoms 2 or more short periods,3=symptoms most of day not affect activities,4=symptoms most of day did affect activities,5=symptoms severe.Overall satisfaction score:0=very dissatisfied,1=dissatisfied,2=slightly dissatisfied,3=neutral,4=slightly satisfied,5=satisfied 6=very satisfied
| Percentage of asthma symptom-free days | Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | Fluticasone Propionate/Salmeterol (FSC) |
|---|---|---|
| Asthma: Mean Change From Baseline at Endpoint in Percentage of Asthma Symptom-Free Days for Per Protocol Population | 34.8 ± 4.32 | 37.1 ± 4.23 |
Endpoint was defined as the average of the data reported from the last week of treatment. Albuterol/salbutamol use (related to percentage of asthma rescue-free days).
| Percentage of rescue-free days | Fluticasone Propionate/Salmeterol (FSC) | Montelukast (MON) |
|---|---|---|
| Asthma: Mean Change From Baseline at Endpoint in Percentage of Albuterol-Salbutamol Free Days for Intent-to-Treat Population | 37.5 ± 2.84 | 26.7 ± 2.92 |
Endpoint was defined as the average of the data reported from the last week of treatment. Albuterol/salbutamol use (related to percentage of asthma rescue-free days).
| Percentage of rescue-free days | Fluticasone Propionate + Salmeterol & Montelukast (FSC+MON) | Fluticasone Propionate/Salmeterol (FSC) |
|---|---|---|
| Asthma: Mean Change From Baseline at Endpoint in Percentage of Albuterol/Salbutamol-Free Days for Per Protocol Population | 41.2 ± 3.97 | 42.9 ± 4.20 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS) | — | 0/182 (0%) | 32/182 (17.6%) |
| Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | — | 1/182 (0.5%) | 32/182 (17.6%) |
| Fluticasone Propionate/Salmeterol (FSC) | — | 1/180 (0.6%) | 42/180 (23.3%) |
| Montelukast (MON) | — | 1/181 (0.6%) | 41/181 (22.7%) |
| Event | Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS) | Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | Fluticasone Propionate/Salmeterol (FSC) | Montelukast (MON) |
|---|---|---|---|---|
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/182 | 0/182 | 1/180 | 0/181 |
| AppendicitisInfections and infestations | 0/182 | 0/182 | 0/180 | 1/181 |
| Spinal fractureInjury, poisoning and procedural complications | 0/182 | 1/182 | 0/180 | 0/181 |
| Event | Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS) | Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | Fluticasone Propionate/Salmeterol (FSC) | Montelukast (MON) |
|---|---|---|---|---|
| HeadacheNervous system disorders | 7/182 | 7/182 | 8/180 | 8/181 |
| NasopharyngitisInfections and infestations | 1/182 | 3/182 | 4/180 | 0/181 |
| SinusitisInfections and infestations | 3/182 | 0/182 | 4/180 | 1/181 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/182 | 1/182 | 4/180 | 3/181 |
| Upper respiratory tract infectionInfections and infestations | 1/182 | 1/182 | 3/180 | 4/181 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 1/182 | 1/182 | 2/180 | 4/181 |
| Sinus headacheNervous system disorders | 0/182 | 2/182 | 3/180 | 1/181 |
| Back painMusculoskeletal and connective tissue disorders | 2/182 | 1/182 | 3/180 | 1/181 |
| DiarrhoeaGastrointestinal disorders | 2/182 | 0/182 | 0/180 | 3/181 |
| VomitingGastrointestinal disorders | 0/182 | 0/182 | 0/180 | 3/181 |
| Age, Continuous(years) | Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | Fluticasone Propionate/Salmeterol (FSC) | Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS) | Montelukast (MON) | Total |
|---|---|---|---|---|---|
| Mean | 33.0 ± 13.54 | 34.5 ± 14.64 | 34.9 ± 12.62 | 34.5 ± 12.47 | 34.2 ± 13.34 |
| Gender(Participants) | Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | Fluticasone Propionate/Salmeterol (FSC) | Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS) | Montelukast (MON) | Total |
|---|---|---|---|---|---|
| Female | 115 | 102 | 120 | 112 | 449 |
| Male | 67 | 78 | 62 | 69 | 276 |
| Race/Ethnicity, Customized(participants) | Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | Fluticasone Propionate/Salmeterol (FSC) | Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS) | Montelukast (MON) | Total |
|---|---|---|---|---|---|
| White | 138 | 138 | 143 | 145 | 564 |
| African American/African Heritage | 34 | 35 | 31 | 30 | 130 |
| American Indian or Alaska Native | 0 | 1 | 1 | 0 | 2 |
| Asian | 9 | 5 | 5 | 5 | 24 |
| Native Hawaiian or other Pacific Islander | 1 | 1 | 1 | 1 | 4 |
| Unknown | 0 | 0 | 1 | 0 | 1 |
Showing the first 100 of 121 sites across 4 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Sep 2005, a primary completion of Oct 2007 and a completion of Oct 2007. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone · Salmeterol Xinafoate · Montelukast